Vertex Pharmaceuticals

740 articles with Vertex Pharmaceuticals

• Vertex Pharmaceuticals Incorporated Hepatitis C Drug Effective In Small Study

  1/9/2006

• Vertex Pharmaceuticals Incorporated Announces Key Business Objectives For 2006 At 24th Annual JPMorgan Healthcare Conference

  1/9/2006

• Vertex Pharmaceuticals Incorporated Announces Webcast Of Its Presentation At The 24th Annual JPMorgan Healthcare Conference

  1/4/2006

• GlaxoSmithKline And Vertex Pharmaceuticals Incorporated Announce Presentation Of Data Supporting Development Of Investigational HIV Protease Inhibitor Brecanavir

  12/16/2005

• GlaxoSmithKline And Vertex Pharmaceuticals Incorporated Announce New Collaboration To Develop And Commercialize VX-409, A Novel Compound For The Treatment Of Pain

  12/13/2005

• Vertex Pharmaceuticals Incorporated Expects $19.5 Million In Milestone Payments

  12/8/2005

• FDA Grants Fast Track Designation To Vertex Pharmaceuticals Incorporated's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950

  12/8/2005

• Vertex Pharmaceuticals Incorporated Announces That VX-680 Demonstrates Effect On Clinically Relevant Biomarker In Phase I Cancer Study

  12/7/2005

• Vertex Pharmaceuticals Incorporated Announces Start Of Phase II Clinical Development For Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950

  12/5/2005

• Vertex Pharmaceuticals Incorporated Announces Start Of Phase II Clinical Development For Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950

  12/5/2005

• Vertex Pharmaceuticals Incorporated Announces Agreements To Exchange Common Stock For $95.0 Million Of Its Convertible Senior Subordinated Notes Due 2011

  11/29/2005

• Vertex Pharmaceuticals Incorporated Announces Webcast Of Its Presentation At Credit Suisse First Boston's Health Care Conference

  11/14/2005

• Vertex Pharmaceuticals Incorporated Release: AASLD Presentations Support The Initiation Of A Broad Phase II Program With VX-950, An Investigational Oral HCV Protease Inhibitor

  11/11/2005

• Vertex Pharmaceuticals Incorporated Announces A Conference Call And Webcast To Review VX- 950 Presentations At The Upcoming AASLD Meeting

  11/9/2005

• Vertex Pharmaceuticals Incorporated Announces Resignation Of N. Anthony Coles, M.D., As Senior Vice President, Commercial Operations

  11/1/2005

• Vertex Pharmaceuticals Incorporated Announces Webcast Of Its Presentation At The MASS Opportunities Biotechnology Investment Conference 2005

  10/31/2005

• Vertex Pharmaceuticals Incorporated Reports Third Quarter 2005 Financial Results

  10/27/2005

• The Day In Review: Biotech Higher While Market Slides

  5/10/2005

• Biotechs Drop Genomics Moniker

  8/10/2004

• Gurus Find Portfolio Cures In Biotech

  6/16/2004